Rationale for bipolar androgen therapy (BAT) for metastatic prostate cancer

John T. IsaacsThe Prostate Cancer Program, The Department of Oncology at the Sidney Kimmel Comprehensive Cancer Center and Brady Urological Institute, The Department of Urology, The Johns Hopkins School of Medicine, Baltimore, MD, USACorrespondence[email protected]

W. Nathaniel BrennenThe Prostate Cancer Program, The Department of Oncology at the Sidney Kimmel Comprehensive Cancer Center and Brady Urological Institute, The Department of Urology, The Johns Hopkins School of Medicine, Baltimore, MD, USA

Samuel R. DenmeadeThe Prostate Cancer Program, The Department of Oncology at the Sidney Kimmel Comprehensive Cancer Center and Brady Urological Institute, The Department of Urology, The Johns Hopkins School of Medicine, Baltimore, MD, USA

References

Schweizer MT, Antonarakis ES, Wang H, Ajiboye AS, Spitz A, Cao H, Luo J, Haffner MC, Yegnasubramanian S, Carducci MA, Eisenberger MA, Isaacs JT, Denmeade SR. Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: results from a pilot clinical study. Sci Transl Med. 2015;7:269ra2. doi:10.1126/scitranslmed. PMID:25568070
PubMed Web of Science ®Google Scholar
Litvinov IV, Vander Griend DJ, Antony L, Dalrymple S, De Marzo AM, Drake CG, Isaacs JT. Androgen receptor as a licensing factor for DNA replication in androgen-sensitive prostate cancer cells. Proc Natl Acad Sci. USA. 2006;103:15085−90. doi:10.1073/pnas.0603057103. PMID:17015840
PubMed Web of Science ®Google Scholar
Vander Griend DJ, Litvinov IV, Isaacs JT. Stabilizing androgen receptor in mitosis inhibits prostate cancer proliferation. Cell Cycle. 2007;6:647−51. doi:10.4161/cc.6.6.4028. PMID: 17387277
PubMed Web of Science ®Google Scholar
D'Antonio JM, Vander Griend DJ, Isaacs JT. DNA licensing as a novel androgen receptor mediated therapeutic target for prostate cancer. Endocr Relat Cancer. 2009;16:325−32. doi:10.1677/ERC-08-0205. PMID:19240183
PubMed Web of Science ®Google Scholar
Isaacs, JT, D'Antonio JM, Chen S, Antony L, Dalrymple SP, Ndikuyeze GH, Luo J, Denmeade SR. Adaptive auto-regulation of androgen receptor provides a paradigm shifting rationale for bipolar androgen therapy (BAT) for castrate resistant human prostate cancer. Prostate. 2012;72:1491−505. doi:10.1002/pros.22504. PMID:22396319
PubMed Web of Science ®Google Scholar
Cai C, He HH, Chen S, Coleman I, Wang H, Fang Z, Chen S, Nelson PS, Liu XS, Brown M, Balk SP. Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase 1. Cancer Cell. 2011;20:457−71. doi:10.1016/j.ccr.2011.09.001. PMID:22014572
PubMed Web of Science ®Google Scholar
Hedayati M, Haffner MC, Coulter JB, Raval RR, Zhang Y, Zhou H, Mian O, Knight EJ, Razavi N, Dalrymple S, Isaacs JT, Santos A, Hales R, Nelson WG, Yegnasubramanian S, DeWeese TL. Androgen deprivation followed by acute androgen stimulation selectively sensitizes AR-positive prostate cancer cells to ionizing radiation. Clin Cancer Res. 2016;22:3310−9. doi:10.1158/1078-0432.CCR-15-1147. PMID:26831716
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Rationale for bipolar androgen therapy (BAT) for metastatic prostate cancer

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Rationale for bipolar androgen therapy (BAT) for metastatic prostate cancer

References

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date